Form 8.3 - Horizon Therapeutics plc

Contacts

Contacts

Contacts

Search

May 19, 2023 10:25 AM Eastern Daylight Time

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	18^th May 2023

2. INTERESTS AND SHORT POSITIONS

Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	4,807,902 (2.102%)		688 (0.000%)
(2) Derivatives (other than options)	-		-
(3) Options and agreements to purchase/sell	662,700 (0.290%)		1,827,000 (0.799%)
Total	5,470,602 (2.391%)		1,827,688 (0.799%)

2. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Ap20

3. DEALINGS (Note 4)

Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Sale	215	101.19
Sale	300	101.42
Sale	200	101.38
Sale	200	101.28
Purchase	42	101.36
Purchase	139	101.25
Sale	200	101.50
Sale	35	101.37
Sale	200	101.14
Sale	300	101.34
Sale	5	101.22
Sale	5	101.24
Sale	105	101.19
Purchase	7	101.52
Sale	200	101.29
Sale	10	101.23
Purchase	5	101.43
Purchase	6	101.47
Sale	15	101.58
Sale	100	101.78
Sale	185	101.59
Sale	203	101.46
Sale	145	101.42
Sale	219	101.38
Sale	460	101.28
Sale	300	101.36
Sale	289	101.49
Sale	100	101.25
Sale	300	101.50
Sale	212	101.41
Sale	500	101.37
Sale	404	101.33
Sale	1,223	101.44
Sale	531	101.35
Sale	85	101.22
Sale	978	101.39
Sale	100	101.12
Sale	600	101.11
Sale	200	101.16
Sale	100	101.13
Sale	100	101.05
Sale	66	101.04
Sale	600	101.30
Sale	200	101.40
Sale	814	101.52
Sale	100	101.29
Sale	300	101.31
Sale	200	101.27
Sale	100	101.47
Sale	110	101.58
Purchase	1,026	101.63
Sale	97	101.65
Sale	100	101.83
Sale	100	101.61
Sale	400	101.32
Sale	56	101.81
Sale	100	101.08
Sale	100	101.84
Sale	100	101.77
Sale	500	101.21
Purchase	1	101.36
Purchase	49	101.20
Purchase	102	101.39
Purchase	1	101.29
Purchase	1	101.43
Purchase	2,337	101.63
Sale	496	101.65
Purchase	1	101.48
Purchase	1	101.32
Purchase	496	101.64
Sale	20	101.80
Sale	380	101.46
Sale	459	101.42
Purchase	100	101.38
Sale	418	101.38
Sale	353	101.28
Purchase	2,100	101.45
Sale	133	101.45
Sale	142	101.36
Sale	1,396	101.17
Sale	700	101.56
Purchase	62	101.49
Sale	616	101.49
Purchase	100	101.25
Sale	100	101.25
Sale	244	101.50
Sale	570	101.41
Sale	3,894	101.37
Sale	285	101.14
Sale	1,180	101.33
Sale	317	101.34
Sale	274	101.20
Sale	539	101.18
Purchase	500	101.09
Sale	1,899	101.09
Purchase	100	101.44
Sale	1,114	101.44
Sale	811	101.22
Purchase	993	101.39
Sale	100	101.39
Sale	300	101.12
Sale	70	101.11
Sale	153	101.24
Purchase	347	101.19
Sale	5,200	101.19
Purchase	100	101.16
Sale	822	101.16
Purchase	378	101.13
Sale	160	101.13
Sale	800	101.04
Sale	584	101.06
Sale	321	101.30
Sale	487	101.52
Sale	1,767	101.29
Sale	1,300	101.31
Sale	196	101.27
Sale	350	101.26
Sale	1,067	101.43
Sale	101	101.02
Sale	81	101.57
Sale	157	101.53
Purchase	1,000	101.47
Sale	553	101.47
Sale	187	101.58
Sale	9,637	101.63
Sale	123	101.65
Sale	100	101.78
Purchase	200	101.48
Sale	594	101.48
Sale	815	101.15
Sale	5,126	100.95
Sale	100	101.60
Sale	800	101.51
Sale	9	101.54
Sale	120	101.73
Sale	200	101.32
Sale	300	101.75
Sale	55	101.76
Purchase	462	101.07
Sale	1,185	101.07
Sale	9	100.91
Sale	1,054	101.74
Sale	835	101.55
Sale	88	100.92
Sale	75	101.81
Sale	100	101.08
Sale	320	101.89
Sale	50	101.79
Sale	150	101.77
Purchase	523	101.10
Sale	220	101.59
Sale	404	101.21
Sale	10	100.90
Sale	10	101.66
Sale	190	101.90
Purchase	200	101.62

b. Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit (USD)

(Note 5)

c. Options transactions in respect of existing relevant securities

Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price (USD)	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
Put Option	Selling	60,000	100.00	American	5/19/2023
Put Option	Purchasing	55,500	100.00	American	6/16/2023
Call Option	Purchasing	75,000	110.00	American	6/16/2023
Put Option	Purchasing	9,000	85.00	American	6/16/2023
Call Option	Selling	80,000	105.00	American	6/16/2023
Call Option	Purchasing	1,500	110.00	American	17/11/2023

ii. Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

d. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	19^th May 2023
Contact name	Stephen Glasper
Telephone number	+44 203 398 2166
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	1,100	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	11,500	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	241,900	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	14,800	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	2,900	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	300	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	300	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	201,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	50,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	29,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	10,000	100.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	3,600	105.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	10,900	105.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	99,500	115.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	300,000	85.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	267,000	100.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	53,500	95.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Written	300	110.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Written	300	110.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Written	400	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	400	110.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	10,000	105.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Written	250,000	70.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Purchased	250,000	85.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Purchased	50,000	90.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	50,000	90.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Purchased	25,000	95.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	25,000	100.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	50,000	100.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Purchased	80,000	101.00	American	5/26/2023
IE00BQPVQZ61	Call Option	Purchased	125,300	110.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Written	150,000	100.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	80,000	105.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Purchased	1,500	110.00	American	17/11/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1100555

Time of Receipt (offset from UTC): 20230519T123426+0100

Millennium Partners, L.P.

Class of relevant security:

Number

Number

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell